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  EVIDENCE-BASED ANSWER 
Naltrexone (ReVia) and nalmefene (Revex) are the most effective agents for treating alcoholism. Acamprosate 
is effective but not available in the United States. Serotonergic agents, selective serotonin reuptake inhibitors 
(SSRIs), and lithium work best in patients with alcoholism and comorbid depression, anxiety, or bipolar disorder. 
Disulfiram (Antabuse) decreases drink frequency, but is no better than placebo for other outcomes. Greater 
effectiveness is achieved when pharmacologic agents are combined with either counseling or Alcoholics 
Anonymous programs. (Grade of recommendation: B, based on multiple randomized controlled studies with 
short and incomplete follow-up of patients.) 
  EVIDENCE SUMMARY 
Naltrexone (50 mg qd), nalmefene (10–80 mg qd), and acamprosate (dose based on patient weight) are all 
superior to placebo and other agents such as the SSRIs, disulfiram, and serotonergic agents in reducing 
relapse rates and the phenomena of craving and in increasing abstinence rates.1-6 For example, naltrexone 
reduces relapse rates by one half to two thirds.4,6 However, these outcomes apply only to patients who 
completed the study protocol; noncompleters accounted for up to more than 50% of study participants. When 
compared with placebo, nalmefene taken for 3 to 24 months significantly reduced relapse without affecting 
abstinence rates or cravings.3 When compared with placebo, disulfiram failed to significantly increase 
abstinence rates or decrease relapse rates or cravings.2 
In European studies, acamprosate taken for 3 to 24 months significantly increased abstinence rates, but did not 
significantly decrease relapse or cravings as compared with placebo.3 Fifteen studies evaluating serotonergic 
agents, lithium, and SSRIs (including citalopram, viqualine, fluoxetine, and others) taken for 2 to 12 weeks have 
shown promise for increasing abstinence rates and decreasing cravings in alcoholic patients with coexisting 
psychiatric conditions such as depression, anxiety, and bipolar disorder.2,7,8 Studies combining pharmacologic 
intervention with Alcoholics Anonymous’s 12-step program or psychological interventions showed the most 
significant effects on decreasing cravings and relapse rates and increasing abstinence rates.2,3,6,9-12 
 
TABLE 
Grade of recommendation based on the evidence 
Agent 
Decreased 
cravings 
at 6 & 12 
months 
Increased 
abstinence 
rates 6 & 
12 months 
Decreased 
relapse 
rates at 6 
& 12 
months 
Comorbidities: 
alcoholism 
with anxiety, 
depression, or 
bipolar 
disorder 
Naltrexone B B B D 
Nalmefene C C B D 
Serotonergics D D D B 
SSRIs D D D B 
Disulfiram C C C D 
Lithium D D D B 
Acamprosate B B C D 
Based on the Oxford Center for Evidence-based Medicine Levels of Evidence (May 2001). 
  RECOMMENDATIONS FROM OTHERS 
According to the American Society of Addiction Medicine, patients who comply with a combination of 
medication, education, and counseling have favorable short-term and long-term benefits.1 Naltraxone and 
acamprosate effectively reduce cravings and increase abstinence. 
Clinical Commentary by William Chavey, MD, at http://www.fpin.org. 
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